Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 13, 2020, the Department of Defense (DOD), on behalf of the U.S. Department of Health and…
On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on…
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the…
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
On Oct. 13, 2020, the National Institute on Drug Abuse (NIDA) and nine other institutes, all part of…
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
On Oct. 12, 2020, the Washington University School of Medicine in St. Louis announced a $14.6 million grant…
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
On Oct. 9, 2020, the CDC released a new National Action Plan that directed federal agencies to accelerate…
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
On Oct. 8, 2020, The New England Journal of Medicine (NEJM) published the final results from the National…
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
On Oct. 8, 2020, Eli Lilly and Incyte shared additional data showing baricitinib in combination with remdesivir reduced…
On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an…